Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of cariprazine as an adjunctive treatment to antidepressant therapy in patients with major depressive disorder

Next Previous
Trial Profile

A phase III trial of cariprazine as an adjunctive treatment to antidepressant therapy in patients with major depressive disorder

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 23 Aug 2016 New trial record
  • 05 Aug 2016 According to an Allergan and Richter joint media release, this is the third phase III trial of cariprazine in adjunctive MDD and the company expects that this trial with previous positive clinical trial will support the regulatory submissions.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top